BioSenic SA provides update on its autoimmune disease

REGULATED INFORMATION The autoimmune disease platform has completed a successful phase IIb trial targeting cGVHD (chronic Graft vs Host Disease), with a...

Related Keywords

Mont Saint Guibert ,Waals Gewest ,Belgium ,Paris ,France General ,France ,French ,Belgian ,Pierre Laurent ,Medsenic Biosenic ,Arthur Rouill ,Bert Bouserie ,Corey Cutler ,Neil Hunter Michelle Boxall ,Louis Victor Delouvrier ,Ann Reum ,Ib Communications ,Newcap Investor Relations Financial Communications ,Harvard Medical School ,International Media Enquiries ,Host Disease ,Euronext Brussels ,Bone Therapeutics ,Arsenic Trioxide ,Stem Cell Transplantation Program ,Dana Farber Cancer Institute ,Harvard Medical ,Graft Versus Host ,Market Access ,Chronic Graft ,Systemic Lupus ,Systemic Sclerosis ,Louvain La Neuve Science Park ,Mesenchymal Stromal Cells ,Graft Versus Host Disease ,Chief Executive ,Belgian Media ,Investor Enquiries ,Media Enquiries ,French Media ,Brussels Stock Exchange Bios ,Biosenic ,